Abstract:Introduction: The study of the pathophysiology study of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. Methods: The humanized APP NL-G-F knock-in mouse line was crossed to the PS19 MAPT P301S , over-expression mouse line to create the dual APPNL-G-F/PS19 MAPTP301S line. The resulting pathologies were characterized by immunochemical methods and PCR. Results: We now report on a double transgenic APP NL-G-F /PS19 MAPT P301S mouse that at 6 months of age exhibits robust A plaque accumulation, intense MAPT pathology, strong inflammation and extensive neurodegeneration. The presence of A pathology potentiated the other major pathologies, including MAPT pathology, inflammation and neurodegeneration. MAPT pathology neither changed levels of amyloid precursor protein nor potentiated A accumulation. Interestingly, study of immunofluorescence in cleared brains indicates that microglial inflammation was generally stronger in the hippocampus, dentate gyrus and entorhinal cortex, which are regions with predominant MAPT pathology. The APP NL-G-F /MAPT P301S mouse model also showed strong accumulation of N 6 -methyladenosine (m 6 A), which was recently shown to be elevated in the AD brain. m 6 A primarily accumulated in neuronal soma, but also co-localized with a subset of astrocytes and microglia. The accumulation of m 6 A corresponded with increases in METTL3 and decreases in ALKBH5, which are enzymes that add or remove m6A from mRNA, respectively. Discussion: Our understanding of the pathophysiology of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. The APP NL-G-F /MAPT P301S mouse recapitulates many features of AD pathology beginning at 6 months of aging, and thus represents a useful new mouse model for the field. Graphical . This figure summarizes the pathophysiological changes occurring in the APP NL-G-F /MAPT P301S mouse model. This model has the humanized APP NL-G-F gene as a knocking. The neurons consequently produce abundant Aβ 40/42 which leads to rapid formation of extracellular Aβ plaques. The accumulation of Aβ stimulates inflammation and also feeds back to neurons to enhance MAPT pathology and neurodegeneration. The neurons over-express P301S MAPT, which leads to rapid formation of MAPT pathologies; the amount of pathology is enhanced modestly by the abundant production and aggregation of Aβ. The MAPT aggregation in the neurons stimulate the accumulation of cytoplasmic m 6 A, presumably as part of the translational stress response. Secreted MAPT stimulates microglial inflammation and astrocytosis. All of these factors accelerate neurodegeneration. The inflammation in this model tends to accumulate most in regions with MAPT pathology, particularly the hippocampus, although some reactive microglia are also observed near Aβ plaques.

Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyloid‐associated pathology

A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

p38α Mitogen-Activated Protein Kinase—An Emerging Drug Target for the Treatment of Alzheimer's Disease

Early Activation of Astrocytes Does Not Affect Amyloid Plaque Load in an Animal Model of Alzheimer’s Disease

Deficiency of IKKβ in neurons ameliorates Alzheimer’s disease pathology in APP- and tau-transgenic mice

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Early amyloid‐induced changes in microglia gene expression in male APP/PS1 mice

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

The P38 Mitogen Activated Protein Kinase Regulates Β-Amyloid Protein Internalization Through the Α7 Nicotinic Acetylcholine Receptor in Mouse Brain.

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

Multiple Inflammatory Profiles of Microglia and Altered Neuroimages in APP/PS1 Transgenic AD Mice.

The p38 mitogen-activated protein kinase signaling pathway is involved in regulating low-density lipoprotein receptor-related protein 1-mediated β-amyloid protein internalization in mouse brain

Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer’s disease pathology

Involvement of p38 MAPK in Synaptic Function and Dysfunction

MKP‐1 Regulates the Inflammatory Activation of Microglia Against Alzheimer's Disease

p38 MAPK‐mediated loss of nuclear RNase III enzyme Drosha underlies amyloid beta‐induced neuronal stress in Alzheimer's disease

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease

P38mapk: Novel Therapeutic Target to Slow the Progression of Alzheimers Disease

P38 Activation Mediates Amyloid-β Cytotoxicity

β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model